• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

标准化屋尘螨提取物特异性免疫疗法。II. 免疫疗法疗效的预测。

Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy.

作者信息

Bousquet J, Hejjaoui A, Clauzel A M, Guérin B, Dhivert H, Skassa-Brociek W, Michel F B

机构信息

Clinique des Maladies Respiratoires, Centre Hospitalier Universitaire, Montpellier, France.

出版信息

J Allergy Clin Immunol. 1988 Dec;82(6):971-7. doi: 10.1016/0091-6749(88)90133-9.

DOI:10.1016/0091-6749(88)90133-9
PMID:3204255
Abstract

House dust mites of the species Dermatophagoides pteronyssinus (Dpt) represent one of the major allergens inducing asthma. However, a strict allergy to Dpt is not always observed in Dpt-allergic patients, since nonallergic and other allergic triggering factors often coexist. It was suggested that specific immunotherapy with house dust-mite extracts is more effective in children than in adults. A controlled study was undertaken in 215 Dpt-allergic patients with asthma ranging in age from 3 to 72 years (mean +/- SD, 28.2 +/- 10.9 years) to investigate parameters that might predict the efficacy of specific immunotherapy before it is started; 171 patients received a rush immunotherapy protocol with a standardized Dpt extract and, subsequently, maintenance injections with 3000 BU of this extract, and 44 patients served as a control group. Before immunotherapy, all patients had a complete evaluation of the severity of asthma by symptom-medication scores and a pulmonary function test, as well as a study of other triggering factors by checking on seasonal and perennial allergens, sinusitis, and other possible causes, such as aspirin intolerance; 196 patients were investigated between 9 and 12 months after the onset of the survey by means of pulmonary function tests and symptom-medication scores. Medications were adapted according to peak flow rates. It was observed that patients with chronic sinusitis, and/or aspirin intolerance, and/or other perennial allergies did not benefit from specific immunotherapy; therefore, the treatment of a major etiologic factor did not demonstrate improvement in the patients.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

屋尘螨中的粉尘螨是诱发哮喘的主要变应原之一。然而,在粉尘螨过敏患者中并非总能观察到对粉尘螨的严格过敏反应,因为非过敏和其他过敏触发因素常常并存。有人提出,用屋尘螨提取物进行特异性免疫疗法对儿童的效果比对成人更好。对215名年龄在3至72岁(平均±标准差,28.2±10.9岁)的粉尘螨过敏哮喘患者进行了一项对照研究,以调查在开始特异性免疫疗法之前可能预测其疗效的参数;171名患者接受了标准化粉尘螨提取物的快速免疫疗法方案,随后用3000 BU的该提取物进行维持注射,44名患者作为对照组。在免疫疗法之前,所有患者都通过症状 - 用药评分和肺功能测试对哮喘严重程度进行了全面评估,还通过检查季节性和常年性变应原、鼻窦炎以及其他可能原因(如阿司匹林不耐受)对其他触发因素进行了研究;196名患者在调查开始后9至12个月通过肺功能测试和症状 - 用药评分进行了调查。药物根据峰值流速进行调整。观察到患有慢性鼻窦炎、和/或阿司匹林不耐受、和/或其他常年性过敏的患者并未从特异性免疫疗法中获益;因此,治疗主要病因因素并未使患者病情得到改善。(摘要截选至250字)

相似文献

1
Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy.标准化屋尘螨提取物特异性免疫疗法。II. 免疫疗法疗效的预测。
J Allergy Clin Immunol. 1988 Dec;82(6):971-7. doi: 10.1016/0091-6749(88)90133-9.
2
Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma.
J Allergy Clin Immunol. 1989 Apr;83(4):797-802. doi: 10.1016/0091-6749(89)90017-1.
3
Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors.韩国单中心过敏性哮喘皮下免疫疗法:疗效、安全性及临床反应预测因素
J Korean Med Sci. 2017 Jul;32(7):1124-1130. doi: 10.3346/jkms.2017.32.7.1124.
4
The effect of house dust mite specific immunotherapy on cysteinyl leukotriene production by blood leukocytes in subjects with perennial allergic rhinitis and asthma.屋尘螨特异性免疫疗法对常年性变应性鼻炎和哮喘患者血液白细胞半胱氨酰白三烯生成的影响。
J Investig Allergol Clin Immunol. 1998 Mar-Apr;8(2):98-104.
5
Evaluation of immune parameters (including specific IgG4) during immunotherapy.免疫治疗期间免疫参数(包括特异性IgG4)的评估。
Allergol Immunopathol (Madr). 1989 May-Jun;17(3):119-27.
6
Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study.舌下免疫疗法对尘螨致敏哮喘儿童的临床及免疫学效应:一项双盲、随机、安慰剂对照研究
Pediatr Allergy Immunol. 2006 Sep;17(6):408-15. doi: 10.1111/j.1399-3038.2006.00443.x.
7
Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study.舌下免疫疗法对哮喘和鼻炎患儿的疗效:一项双盲、安慰剂对照研究。
Pediatr Pulmonol. 2001 Jul;32(1):49-55. doi: 10.1002/ppul.1088.
8
[Efficacy and safety of sublingual immunotherapy with house dust mite extract in poly allergen sensitized children with allergic rhinitis].尘螨提取物舌下免疫治疗对多过敏原致敏性变应性鼻炎儿童的疗效及安全性
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012 Oct;26(20):913-6.
9
Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens.尘螨皮下免疫疗法治疗变应性鼻炎和哮喘患儿的临床反应与热带无爪螨过敏原致敏无关。
Int Arch Allergy Immunol. 2019;178(2):201-210. doi: 10.1159/000494389. Epub 2018 Dec 13.
10
A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects.一项使用标准化、部分纯化的屋尘螨提取物进行免疫治疗的对照剂量反应研究:临床疗效与副作用
J Allergy Clin Immunol. 1993 Mar;91(3):709-22. doi: 10.1016/0091-6749(93)90190-q.

引用本文的文献

1
Effectiveness and safety of a microcrystalline tyrosine-adjuvanted Dermatophagoides pteronyssinus allergoid immunotherapy in adult patients with allergic asthma and rhinitis: A real-life prospective observational study.微晶酪氨酸佐剂的屋尘螨变应原疫苗免疫疗法在成年过敏性哮喘和鼻炎患者中的有效性和安全性:一项真实世界前瞻性观察研究。
Immun Inflamm Dis. 2022 May;10(5):e585. doi: 10.1002/iid3.585.
2
Insights Into Mucosal Innate Immune Responses in House Dust Mite-Mediated Allergic Asthma.深入了解屋尘螨介导的变应性哮喘中的黏膜先天免疫反应。
Front Immunol. 2020 Dec 7;11:534501. doi: 10.3389/fimmu.2020.534501. eCollection 2020.
3
Subcutaneous immunotherapy induces alterations in monocytes and dendritic cells homeostasis in allergic rhinitis patients.
皮下免疫疗法可诱导变应性鼻炎患者单核细胞和树突状细胞稳态发生改变。
Allergy Asthma Clin Immunol. 2018 Nov 15;14:45. doi: 10.1186/s13223-018-0271-8. eCollection 2018.
4
Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews.变应性哮喘的变应原免疫治疗:系统评价的系统概述
Clin Transl Allergy. 2017 Aug 2;7:25. doi: 10.1186/s13601-017-0160-0. eCollection 2017.
5
Asthma in children and adolescents: a comprehensive approach to diagnosis and management.儿童和青少年哮喘:诊断和管理的综合方法。
Clin Rev Allergy Immunol. 2012 Aug;43(1-2):98-137. doi: 10.1007/s12016-011-8261-3.
6
The inverse association between the presence of antibody to hepatitis B surface antigen and atopy in young adults.年轻成年人中乙肝表面抗原抗体的存在与特应性之间的负相关。
Korean J Intern Med. 2005 Sep;20(3):210-6. doi: 10.3904/kjim.2005.20.3.210.
7
Minimising the risks of allergen-specific injection immunotherapy.将变应原特异性注射免疫疗法的风险降至最低。
Drug Saf. 2000 Oct;23(4):323-32. doi: 10.2165/00002018-200023040-00005.
8
Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.《1999年加拿大哮喘共识报告》。加拿大哮喘共识小组。
CMAJ. 1999 Nov 30;161(11 Suppl):S1-61.
9
Immunotherapy in asthma.哮喘的免疫疗法
Thorax. 1997 Aug;52 Suppl 3(Suppl 3):S22-9. doi: 10.1136/thx.52.2008.s22.
10
Specific immunotherapy in house dust mite allergy.室内尘螨过敏的特异性免疫疗法。
Clin Rev Allergy Immunol. 1995 Summer;13(2):151-9. doi: 10.1007/BF02758099.